Heat Biologics, Inc., a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, and its subsidiary, Pelican Therapeutics, have entered a manufacturing agreement with KBI Biopharma to advance cancer-targeting immunotherapies. 
 
Last year, Pelican was awarded a $15.2 million grant from the Cancer Prevention and Research Institute of Texas to support manufacturing efforts, as well as to complete a 70-patient, Phase I trial. Under the agreement, KBI Biopharma will provide comprehensive development and manufacturing services in an effort to increase speed, productivity, stability and flexibility over traditional approaches to cell line development.

KBI is a biopharmaceutical CDMO that specializes in advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes. KBI operates four facilities in Durham and Research Triangle Park, NC, Boulder, CO, and The Woodlands, TX.